Anticoagulant Agents in Acute Coronary Syndromes

Current Problems in Cardiology

Volumn 36, Issue 4, 2011, Pages 127-168

  Sakhuja, Rahul ^a   Yeh, Robert W ^a   Bhatt, Deepak L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; DALTEPARIN; DESULFATOHIRUDIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; OTAMIXABAN; PARNAPARIN; PLACEBO; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; REVIPARIN; RIVAROXABAN; SEMULOPARIN; THROMBIN INHIBITOR; TINZAPARIN; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGINA PECTORIS; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INDICATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK POPULATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; HUMANS; TREATMENT OUTCOME;

EID: 79955967892     PISSN: 01462806     EISSN: 15356280     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2011.03.003     Document Type: Article

References (110)

1. Fuster V., Moreno P.R., Fayad Z.A., et al. Atherothrombosis and high-risk plaque: part I: Evolving concepts. J Am Coll Cardiol 2005, 46:937-954.
2. Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res 2009, 50(suppl):S352-S357.
3. Virmani R., Burke A.P., Farb A., et al. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006, 47:C13-C18.
4. Sakhuja R., Yeh R.W., Bhatt D.L. Antiplatelet agents in acute coronary syndromes. Curr Probl Cardiol 2010, 35:123-170.
5. Telford A.M., Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981, 1:1225-1228.
6. Théroux P., Ouimet H., McCans J., et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988, 319:1105-1111.
7. Cohen M., Adams P.C., Parry G., et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994, 89:81-88.
8. Holdright D., Patel D., Cunningham D., et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994, 24:39-45.
9. Oler A., Whooley M.A., Oler J., et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996, 276:811-815.
10. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1990, 336:65-71.
11. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992, 339:753-770.
12. Collins R., MacMahon S., Flather M., et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996, 313:652-659.
13. Granger C.B., Hirsch J., Califf R.M., et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996, 93:870-878.
14. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993, 329:673-682.
15. Liem A., Zijlstra F., Ottervanger J.P., et al. High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: the heparin in Early Patency (HEAP) randomized trial. J Am Coll Cardiol 2000, 35:600-604.
16. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998, 338:1488-1497.
17. Dangas G. Predictors of stent thrombosis after primary angioplasty in acute MI: the HORIZONS-AMI trial [Abstract Number 2406]. Presented at: American College of Cardiology Annual Scientific Session, Orlando, Florida, 2009. Accessed 2010.
18. Théroux P., Waters D., Lam J., et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992, 327:141-145.
19. Gore J.M., Spencer F.A., Gurfinkel E.P., et al. Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]) (From the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol 2009, 103:175-180.
20. Matsuo T., Tomaru T., Kario K., et al. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome. Thromb Res 2005, 115:475-481.
21. Bijsterveld N.R., Moons A.H., Meijers J.C., et al. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002, 39:811-817.
22. Martel N., Lee J., Wells P.S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005, 106:2710-2715.
23. Antman E.M., Cohen M., Radley D., et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999, 100:1602-1608.
24. Antman E.M., Cohen M., McCabe C., et al. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002, 23:308-314.
25. Ferguson J.J., Califf R.M., Antman E.M., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004, 292:45-54.
26. Mahaffey K.W., Cohen M., Garg J., et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 2005, 294:2594-2600.
27. White H.D., Kleiman N.S., Mahaffey K.W., et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of enoxaparin, revascularization and glycoprotein IIb/IIIa inhibitors (SYNERGY) trial. Am Heart J 2006, 152:1042-1050.
28. Cohen M., Mahaffey K.W., Pieper K., et al. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2006, 48:1346-1354.
29. Drouet L., Bal dit Sollier C., Martin J. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study. Am Heart J 2009, 158:177-184.
30. Petersen J.L., Mahaffey K.W., Hasselblad V., et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA 2004, 292:89-96.
31. Klein W., Buchwald A., Hillis S.E., et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997, 96:61-68.
32. Comparison of two treatment durations (6 days14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. Eur Heart J 1999, 20:1553-1562.
33. Katsouras C., Michalis L.K., Papamichael N., et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months. Am Heart J 2005, 150:385-391.
34. Cohen M., Gensini G.F., Maritz F., et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003, 42:1348-1356.
35. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006, 354:1477-1488.
36. Zeymer U., Gitt A., Jünger C., et al. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction. Thromb Haemost 2008, 99:150-154.
37. Gibson C.M., Murphy S.A., Montalescot G., et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007, 49:2238-2246.
38. Yusuf S., Mehta S.R., Xie C., et al. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005, 293:427-435.
39. Frostfeldt G., Ahlberg G., Gustafsson G., et al. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction---a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999, 33:627-633.
40. Wang X.K., Zhang Y., Yang C.M., et al. Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction. Clin Drug Invest 2006, 26:341-349.
41. Murphy S.A., Gibson C.M., Morrow D.A., et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007, 28:2077-2086.
42. De Luca G., Marino P. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials. Am Heart J 2007, 154(1085):e1-e6.
43. Hirsh J., Dalen J., Anderson D.R., et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001, 119:8S-21S.
44. Effects of long-termmoderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. J Am Coll Cardiol 2001, 37:475-484.
45. Brouwer M.A., van den Bergh P.J., Aengevaeren W.R., et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the antithrombotics in the Prevention of reocclusion in Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 2002, 106:659-665.
46. Hurlen M., Abdelnoor M., Smith P., et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002, 347:969-974.
47. van Es R.F., Jonker J.J., Verheugt F.W., et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002, 360:109-113.
48. Andreotti F., Testa L., Biondi-Zoccai G.G., et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006, 27:519-526.
49. Depta J.P., Cannon C.P., Fonarow G.C., et al. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol 2009, 104:1171-1178.
50. Manzano-Fernández S., Pastor F.J., Marin F., et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008, 134:559-567.
51. Rogacka R., Chieffo A., Michev I., et al. Dual antiplatelet therapy aftery percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. J Am Coll Cardiol Intv 2008, 1:56-61.
52. Nguyen M.C., Lim Y.L., Walton A., et al. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. Eur Heart J 2007, 28:1717-1722.
53. Triple therapy in patients on oral anticoagulation after drug eluting stent implantation (ISAR-TRIPLE) Accessed April 29. http://www.clinicaltrials.gov/ct2/show/NCT00776633.
54. WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing? Accessed April 29. http://www.clinicaltrials.gov/ct2/show/NCT00769938.
55. Ongoing WAR-farin and coronary STENTing: a multicenter, prospective registry on antithrombotic treatment War-Stent Investigators, Accessed April 29. http://www.clinicaltrials.gov/ct2/show/NCT00722319.
56. Schwalm J.D., Ahmad M., Salehian O., et al. Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. J Thromb Thrombolysis 2010, 30(2):127-132.
57. Gurm H.S., Bhatt D.L. Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors. Am Heart J 2005, 149:S43-S53.
58. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002, 359:294-302. Direct Thrombin Inhibitor Trialists' Collaborative Group.
59. Robson R., White H., Aylward P., et al. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 2002, 71:433-439.
60. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355:2203-2216.
61. Lincoff A.M., Steinhubl S.R., Manoukian S.V., et al. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. JACC Cardiovasc Interv 2008, 1:639-648.
62. Stone G.W., Ware J.H., Bertrand M.E., et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007, 298:2497-2506.
63. Stone G.W., White H.D., Ohman E.M., et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007, 369:907-919.
64. White H.D., Ohman E.M., Lincoff A.M., et al. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008, 52:807-814.
65. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358:2218-2230.
66. Mehran R., Lansky A.J., Witzenbichler B., et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009, 374:1149-1159.
67. Dangas G., Mehran R., Guagliumi G., et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2009, 54:1438-1446.
68. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001, 358:1855-1863. Hirulog and Early Reperfusion or Occlusion (H.E.R.O.)-2 Trial Investigators.
69. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/non-ST-Elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007, 50:e1-e157.
70. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004, 44:E1-E211.
71. Antman E.M., Hand M., Armstrong P.W., et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008, 51:210-247.
72. Markwardt F. Hirudin as alternative anticoagulant-a historical review. Semin Thromb Hemost 2002, 28:405-414.
73. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary arteries (GUSTO) IIb investigators. N Engl J Med 1996, 335:775-782.
74. Effects of Recombinant Hirudin (Lepirudin) Compared with Heparin on Death, Myocardial Infarction, Refractory Angina, and Revascularisation Procedures in Patients with Acute Myocardial Ischaemia Without ST Elevation: a Randomised Trial. Lancet 1999, 353:429-438. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators.
75. Antman E.M. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996, 94:911-921.
76. Neuhaus K.L., Molhoek G.P., Zeymer U., et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. J Am Coll Cardiol 1999, 34:966-973.
77. Lowry F. Concerns over stroke, bleeding, and lepirudin voiced by FDA Cardio-Renal Drug Advisory Committee Accessed. http://www.theheart.org/article/297553.do.
78. Yeh R.W., Jang I.K. Argatroban: update. Am Heart J 2006, 151:1131-1138.
79. Kaplinsky E. Direct antithrombin-argatroban in acute myocardial infarction (ARGAMI-2). J Am Coll Cardiol 1998, 32:1-7.
80. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008, 47:285-295.
81. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
82. Re-Deem D. Finding Study for Dabigatran Etexilate in Patients with Acute Coronary Syndrome Accessed April 3. http://www.clinicaltrials.gov/ct2/show/NCT00621855.
83. Turpie A.G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007, 27:1238-1247.
84. Rajagopal V., Bhatt D.L. Factor Xa inhibitors in acute coronary syndromes: moving from mythology to reality. J Thromb Haemost 2005, 3:436-438.
85. Donat F., Duret J.P., Santoni A., et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002, 41(suppl 2):1-9.
86. Warkentin T.E., Maurer B.T., Aster R.H. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007, 356:2653-2655. [Discussion 2653-5].
87. Yusuf S., Mehta S.R., Chrolavicius S., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006, 354:1464-1476.
88. Mehta S.R., Granger C.B., Eikelboom J.W., et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007, 50:1742-1751.
89. Yusuf S., Mehta S.R., Chrolavicius S., et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006, 295:1519-1530.
90. Peters R.J., Joyner C., Bassand J.P., et al. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur Heart J 2008, 29:324-331.
91. Oldgren J., Wallentin L., Afzal R., et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur Heart J 2008, 29:315-323.
92. Fondaparinux Trial with UFH during revascularization in Acute coronary synromes (FUTURA): a prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high risk patients with UA/NSTEMI initially treated with subcutaneous fondaparinux and referred for early Accessed April 29. http://www.clinicaltrials.gov/ct2/show/NCT00790907.
93. Eikelboom J.W., Weitz J.I. New anticoagulants. Circulation 2010, 121:1523-1532.
94. Kubitza D., Becka M., Mueck W., et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol 2006, 46:981-990.
95. Kubitza D., Becka M., Voith B., et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005, 78:412-421.
96. Mega J.L., Braunwald E., Mohanavelu S., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009, 374:29-38.
97. A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary Syndrome Accessed April 29. http://www.clinicaltrials.gov/ct2/show/NCT00809965.
98. Raghavan N., Frost C.E., Yu Z., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009, 37:74-81.
99. Apixaban for Prevention of Acute Ischemic Events-2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban in Subjects with a Recent Acute Coronary Syndrome Accessed April 29. http://www.clinicaltrials.gov/ct2/show/NCT00831441.
100. Cohen M., Bhatt D.L., Alexander J.H., et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 2007, 115:2642-2651.
101. Sabatine M.S., Antman E.M., Widimsky P., et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009, 374:787-795.
102. Stassens P., Bergum P.W., Gansemans Y., et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci USA 1996, 93:2149-2154.
103. Giugliano R.P., Wiviott S.D., Stone P.H., et al. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol 2007, 49:2398-2407.
104. Rao S.V., Melloni C., Myles-Dimauro S., et al. Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. Circulation 2010, 121:1713-1721.
105. Safety and Efficacy of TAK-442 in Subjects with Acute Coronary Syndromes Accessed April 29. http://clinicaltrials.gov/ct2/show/NCT00677053.
106. Morrow D.A., Murphy S.A., McCabe C.H., et al. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. Eur Heart J 2005, 26:682-688.
107. Chan M.Y., Cohen M.G., Dyke C.K., et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008, 117:2865-2874.
108. Garcia D., Libby E., Crowther M.A. The new oral anticoagulants. Blood 2010, 115:15-20.
109. Fox K.A., Steg P.G., Eagle K.A., et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007, 297:1892-1900.
110. Rogers W.J., Frederick P.D., Stoehr E., et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008, 156:1026-1034.